This report examines the productivity and output of the oncology pipeline, new treatment mechanisms, and which patients will likely benefit from new therapies. Our research brings into focus the amount spent on oncology medicines globally, clinical trial activity, complexity and success, and the outlook through 2023. The report also addresses shifts in therapy use with the emergence of immuno-therapies, Next-Generation Biotherapeutics and biosimilars.
Interested in learning more about how IQVIA can create solutions to help you drive healthcare forward?
We're available during standard business hours.
U.S. Toll-Free only
+1 866 267 4479
For international call please find a number in our toll-free list.
The IQVIA Institute for Human Data Science contributes to the advancement of human health globally through timely research, insightful analysis and scientific expertise applied to granular non-identified patient-level data.